Table 4.
Questions on PSA testing II by general practitioners and urologists, n (%)
| Question | Categories | GPs | Urologists | ||||
|---|---|---|---|---|---|---|---|
| Never + Rarely | Sometimes | Always + Often | Never + Rarely | Sometimes | Always + Often | ||
| On which occasions do you inform your patient on PSA testing? | Within an early cancer detection examination | 6 (14.6) | 4 (9.8) | 31 (75.6) | 0 (0.0) | 0 (0.0) | 14 (100.0) |
| In case of a positive family anamnesis | 6 (14.7) | 4 (9.8) | 31 (75.7) | 0 (0.0) | 1 (7.1) | 13 (92.9) | |
| In case of discomfort in the lower urinary tract | 16 (39.1) | 8 (19.5) | 17 (41.5) | 1 (7.1) | 2 (14.3) | 11 (78.5) | |
| In case of unclear discomfort | 17 (41.5) | 10 (24.4) | 14 (34.2) | 1 (7.1) | 3 (21.4) | 10 (71.4) | |
| How often do you discuss the following aspects with your patients before performing a PSA test? | Impact on overall mortality | 14 (34.2) | 4 (9.8) | 23 (56.1) | 2 (14.2) | 3 (21.4) | 9 (64.3) |
| Impact on disease-specific mortality | 7 (17.1) | 3 (7.3) | 31 (75.6) | 2 (14.2) | 1 (7.1) | 11 (78.6) | |
| Impact on risk of metastasis | 9 (22.0) | 8 (19.5) | 24 (58.6) | 1 (7.1) | 1 (7.1) | 12 (85.7) | |
| Potential overdiagnosis | 3 (7.3) | 5 (12.2) | 33 (80.5) | 2 (14.2) | 1 (7.1) | 11 (78.6) | |
| Issue of false positives | 0 (0.0) | 6 (14.6) | 35 (85.4) | 0.0 (0) | 0 (0.0) | 14 (100.0) | |
| Potential anxiety during waiting on test result | 13 (31.7) | 6 (14.6) | 22 (53.7) | 6 (42.9) | 1 (7.1) | 7 (50.0) | |
| Potential follow-up examinations if the test result is conspicuous | 1 (2.4) | 8 (19.5) | 32 (78.0) | 0 (0.0) | 1 (7.1) | 13 (92.8) | |
| Adverse effects of the treatment | 5 (12.2) | 12 (29.3) | 24 (58.5) | 0 (0.0) | 6 (42.9) | 8 (57.1) | |
Abbreviations: GPs, general practitioners; PSA, prostate-specific antigen.